Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition
| Autor: | Matt Biery, Joyoti Dey, Derek Thirstrup, Richard A. Klinghoffer, Joseph Casalini, Sally Ditzler, Angela Merrell, Marc Grenley |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Drug
Cancer Research Chemotherapy Proteasome Inhibition 010405 organic chemistry business.industry media_common.quotation_subject medicine.medical_treatment Cancer Disease Pharmacology medicine.disease 01 natural sciences 0104 chemical sciences 010404 medicinal & biomolecular chemistry Oncology Cancer research Medicine Stage (cooking) business CDK inhibitor Triple-negative breast cancer media_common |
| Zdroj: | Cancer Research. 76:2835-2835 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | Triple negative breast cancer (TNBC) is a highly heterogeneous disease, notoriously challenging to treat with standard chemotherapy options, and therefore is an area of intense focus for discovery of novel effective combination therapies. Here we used a previously described technology platform called CIVO, which enables assessment of multiple drugs and drug combinations simultaneously in living tumors, to identify drug combinations that result in synergistic anti-tumor activity in the HCC1187 model of TNBC. Our study focused on agents that combine with Voruciclib, a novel clinical stage oral CDK inhibitor with potent activity ( Citation Format: Joyoti Dey, Joseph Casalini, Sally Ditzler, Matt Biery, Angela Merrell, Derek Thirstrup, Marc Grenley, Richard Klinghoffer. Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2835. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|